Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Lung ultrasonography: A prognostic tool in non-ICU hospitalized patients with COVID-19 pneumonia

Francesco Casella a,*, Marco Barchiesi a, Federica Leidi a, Giulia Russo a, Giovanni Casazza b, Giulia Valerio a, Daniela Torzillo a, Elisa Ceriani a, Marta Del Medico a, Anna Maria Brambilla c, Maria Alessandra Mazziotti c, Chiara Cogliati a

a Department of Internal Medicine, Luigi Sacco Hospital, ASST-FBF-Sacco, Milan, Italy
b Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università degli Studi di Milano, Milan, Italy
c Emergency Medicine Unit, Luigi Sacco Hospital, ASST-FBF-Sacco, Milan, Italy

ABSTRACT

Background: High diagnostic accuracy for pneumonia, absence of radiation exposure and repeatability are intrinsic features of lung ultrasonography making it an attractive tool in the assessment of patients with COVID-19 pneumonia. The aim of our prospective, observational study was to detect COVID-19-associated sonographic features and assess the potential value of LUS in predicting adverse events.

Methods: From March 12th to April 20th 2020 patients admitted to two medium-intensive wards with a discharge diagnosis of COVID-19 pneumonia were enrolled and underwent lung ultrasonography. The prognostic value of several ultrasonographic scores at admission and after 72 hours from the first examination (the total score, the anterolateral score, the number of positive region and the presence of consolidation) were analysed with logistic regression along with other potential prognostic factors. The primary outcome was a composite of death and transfer to Intensive Care Unit (ICU), while the secondary was continuous positive airways pressure (CPAP) support.

Results: 190 patients were enrolled in the study. The primary outcome was seen in 25 patients (13%), the secondary outcome in 36 (22%). At multivariate regression no sonographic score at admission was independently correlated with the primary outcome while the total score, the anterolateral score, the number of positive regions were associated with CPAP support. When considering the subgroup of patients undergoing lung ultrasonography after 72 hours (128 patients) the total score was independently associated with both the primary and secondary outcome.

Conclusion: Lung ultrasonography can be a promising prognostic tool in patients admitted to non-ICU units for COVID-19 pneumonia.

1. Introduction

From February to March 2020, Italy became the most affected country worldwide by coronavirus disease (COVID-19). Our healthcare system was put under enormous pressure, especially in Lombardia which accounts for almost half of the deaths of the entire country [1]. In this setting, early identification of suspected cases, assessment of disease severity and monitoring patients affected by COVID-19 pneumonia became crucial. Lung computed tomography (CT) is considered the gold standard to detect pulmonary lesions in patients with COVID-19 pneumonia; patients typically show bilateral, multilobar ground-glass opacities, with a prevalent peripheral distribution, which can progress to crazy paving and consolidations [2,3]. Nevertheless, the pandemic spread of the disease in many cases did not allow a standardized CT-based diagnostic approach due to either overcrowding of Emergency Department (ED) and high risk of transporting contagious and unstable patients to radiology department.

In the last decades, lung ultrasound (LUS) represented a reliable imaging tool to differentiate causes of acute dyspnoea and acute respiratory failure [4] and to monitor lung involvement in hospitalized patients [5,6]. Moreover it was shown to be an accurate tool for diagnosis and follow-up of pneumonia [7,8]. It is performed at bedside, usually with portable US devices, thus minimizing the risk associated with transfer of infectious and potentially critical/unstable patients. It is known that one of the major LUS limits is its possibility to only detect abnormalities reaching the pleural line; nevertheless, COVID-19 pulmonary involvement seems to start from the peripheral lung regions [9], allowing a reliable US assessment. For these reasons, LUS encountered growing enthusiasm for its application in COVID-19 affected patients. Peng et al. first described their experience in the use of LUS in China, suggesting its use as alternative to other conventional imaging methods [10]. Two recent studies reported a good correlation between LUS and CT findings [11,12].

The most frequently reported LUS features in COVID-19 patients are the following: interstitial involvement represented by B-lines pattern (i.e. the presence of at least three B-lines in a lung scan) which can progress...
As shown, literature on LUS in COVID-19 patients is rapidly growing; however few studies evaluated the prognostic value of LUS in COVID-19 patients [20–23]. All these studies enrolled a significant percentage of patients who were hospitalized in Intensive Care Units (ICU). An Italian study outlined the prognostic role of LUS in a cohort of patients in the Emergency Department [24].

In our study we aimed to detect COVID-19 associated sonographic features and assess the potential value of LUS in predicting adverse events in a cohort of patients hospitalized in a medium-intensity department.

2. Materials and methods

The study is part of a single-centre, prospective, observational, cohort study of all the adult COVID-19 patients admitted to Luigi Sacco Hospital in Milan, Italy, since February 21st 2020; the observation of the cohort was censored on April 20th 2020. COVID-19 infection was defined by a positive RT-PCR assay according to WHO criteria [25]. The data extracted from the patients’ clinical charts on a daily basis and stored in an ad hoc database included demographic, clinical, radiological and pharmacological data. The study was approved by the local Ethics Committee and informed consent was obtained (Protocol Number 16088/2020).

LUS was routinely performed in the subgroup of patients admitted to our two Internal Medicine Departments which were converted into COVID-19 medium-intensity care units. Thus we considered adult patients consecutively hospitalized with a diagnosis (imaging/clinical derived) of COVID-19 related pneumonia.

Pre-existing conditions that may mislead the evaluation of lung ultrasound (i.e. congestive heart failure, lung neoplasms, pre-existing lung interstitial diseases) were considered exclusion criteria.

Age, Charlson Comorbidity Index (CCI), presence of hypertension, obesity (expressed as body mass index, BMI) and arterial oxygen partial pressure/fractional inspired oxygen ratio (P/F) were analysed because of the increasing evidences of their connection to poor outcome in COVID-19 patients.

2.1. Lung ultrasound

As defined by local clinical practise protocol, patients underwent lung ultrasound examination within 48 hours from admission.

A subgroup of patients underwent other LUS examinations, the first one performed after 72 hours from admission LUS. Other LUS exams were performed according to physician decision. Every performed LUS was recorded in the patient electronic clinical record; images (pictures or videos) were properly stored.

LUS was performed by physicians trained in point of care ultrasound and particularly in lung examinations. The physicians were not blind to the clinical and radiological status of patients. Nevertheless, a second, blind independent observer with more than 10 years certified experience in lung ultrasound reviewed 5% of the recorded scans to assess reproducibility of LUS. The scans were randomly chosen for the review.

LUS was performed with different models of portable ultrasound devices: Philips CX50, GE Logiq F6 and Vinno 8, using convex probes for a thorough evaluation of both lungs. US machines setting were optimized following the subsequent modalities: low mechanical index (0.7 or less); a single focus, positioned on the pleural line; no harmonic modulation; no persistence.

The exam was conducted by dividing the chest wall in 12 regions, six for each lung: two anterior (upper and lower), two lateral and two posterior regions as described before [26]. In details, the anterior axillary line was used to divide anterior and lateral regions, the posterior axillary line divided lateral and posterior regions, while the inter nipple line split upper and lower areas.

Anteralateral and posterior regions were evaluated in supine and sitting position, respectively. When patients were unable to maintain a sitting position, posterior regions were evaluated with the patients in left sitting position. The patients were asked to breathe in and out deeply before scanning.

The exam was performed by a physician trained in ultrasound who had participated in a dedicated master course. After each LUS exam, the findings were registered in the electronic clinical chart.

The study is part of a single-centre, prospective, observational, cohort study of all the adult COVID-19 patients admitted to Luigi Sacco Hospital in Milan, Italy, since February 21st 2020; the observation of the cohort was censored on April 20th 2020. COVID-19 infection was defined by a positive RT-PCR assay according to WHO criteria [25]. The data extracted from the patients’ clinical charts on a daily basis and stored in an ad hoc database included demographic, clinical, radiological and pharmacological data. The study was approved by the local Ethics Committee and informed consent was obtained (Protocol Number 16088/2020).

LUS was routinely performed in the subgroup of patients admitted to our two Internal Medicine Departments which were converted into COVID-19 medium-intensity care units. Thus we considered adult patients consecutively hospitalized with a diagnosis (imaging/clinical derived) of COVID-19 related pneumonia.

Pre-existing conditions that may mislead the evaluation of lung ultrasound (i.e. congestive heart failure, lung neoplasms, pre-existing lung interstitial diseases) were considered exclusion criteria.

Age, Charlson Comorbidity Index (CCI), presence of hypertension, obesity (expressed as body mass index, BMI) and arterial oxygen partial pressure/fractional inspired oxygen ratio (P/F) were analysed because of the increasing evidences of their connection to poor outcome in COVID-19 patients.

2.1. Lung ultrasound

As defined by local clinical practise protocol, patients underwent lung ultrasound examination within 48 hours from admission.

A subgroup of patients underwent other LUS examinations, the first one performed after 72 hours from admission LUS. Other LUS exams were performed according to physician decision. Every performed LUS was recorded in the patient electronic clinical record; images (pictures or videos) were properly stored.

LUS was performed by physicians trained in point of care ultrasound and particularly in lung examinations. The physicians were not blind to the clinical and radiological status of patients. Nevertheless, a second, blind independent observer with more than 10 years certified experience in lung ultrasound reviewed 5% of the recorded scans to assess reproducibility of LUS. The scans were randomly chosen for the review.

LUS was performed with different models of portable ultrasound devices: Philips CX50, GE Logiq F6 and Vinno 8, using convex probes for a thorough evaluation of both lungs. US machines setting were optimized following the subsequent modalities: low mechanical index (0.7 or less); a single focus, positioned on the pleural line; no harmonic modulation; no persistence.

The exam was conducted by dividing the chest wall in 12 regions, six for each lung: two anterior (upper and lower), two lateral and two posterior regions as described before [26]. In details, the anterior axillary line was used to divide anterior and lateral regions, the posterior axillary line divided lateral and posterior regions, while the inter nipple line split upper and lower areas.

Anteralateral and posterior regions were evaluated in supine and sitting position, respectively. When patients were unable to maintain a sitting position, posterior regions were evaluated with the patients in left sitting position. The patients were asked to breathe in and out deeply before scanning.

The study is part of a single-centre, prospective, observational, cohort study of all the adult COVID-19 patients admitted to Luigi Sacco Hospital in Milan, Italy, since February 21st 2020; the observation of the cohort was censored on April 20th 2020. COVID-19 infection was defined by a positive RT-PCR assay according to WHO criteria [25]. The data extracted from the patients’ clinical charts on a daily basis and stored in an ad hoc database included demographic, clinical, radiological and pharmacological data. The study was approved by the local Ethics Committee and informed consent was obtained (Protocol Number 16088/2020).

LUS was routinely performed in the subgroup of patients admitted to our two Internal Medicine Departments which were converted into COVID-19 medium-intensity care units. Thus we considered adult patients consecutively hospitalized with a diagnosis (imaging/clinical derived) of COVID-19 related pneumonia.

Pre-existing conditions that may mislead the evaluation of lung ultrasound (i.e. congestive heart failure, lung neoplasms, pre-existing lung interstitial diseases) were considered exclusion criteria.

Age, Charlson Comorbidity Index (CCI), presence of hypertension, obesity (expressed as body mass index, BMI) and arterial oxygen partial pressure/fractional inspired oxygen ratio (P/F) were analysed because of the increasing evidences of their connection to poor outcome in COVID-19 patients.

2.1. Lung ultrasound

As defined by local clinical practise protocol, patients underwent lung ultrasound examination within 48 hours from admission.

A subgroup of patients underwent other LUS examinations, the first one performed after 72 hours from admission LUS. Other LUS exams were performed according to physician decision. Every performed LUS was recorded in the patient electronic clinical record; images (pictures or videos) were properly stored.

LUS was performed by physicians trained in point of care ultrasound and particularly in lung examinations. The physicians were not blind to the clinical and radiological status of patients. Nevertheless, a second, blind independent observer with more than 10 years certified experience in lung ultrasound reviewed 5% of the recorded scans to assess reproducibility of LUS. The scans were randomly chosen for the review.

LUS was performed with different models of portable ultrasound devices: Philips CX50, GE Logiq F6 and Vinno 8, using convex probes for a thorough evaluation of both lungs. US machines setting were optimized following the subsequent modalities: low mechanical index (0.7 or less); a single focus, positioned on the pleural line; no harmonic modulation; no persistence.

The exam was conducted by dividing the chest wall in 12 regions, six for each lung: two anterior (upper and lower), two lateral and two posterior regions as described before [26]. In details, the anterior axillary line was used to divide anterior and lateral regions, the posterior axillary line divided lateral and posterior regions, while the inter nipple line split upper and lower areas.

Anteralateral and posterior regions were evaluated in supine and sitting position, respectively. When patients were unable to maintain a sitting position, posterior regions were evaluated with the patients in left sitting position. The patients were asked to breathe in and out deeply before scanning.

The exam was conducted by dividing the chest wall in 12 regions, six for each lung: two anterior (upper and lower), two lateral and two posterior regions as described before [26]. In details, the anterior axillary line was used to divide anterior and lateral regions, the posterior axillary line divided lateral and posterior regions, while the inter nipple line split upper and lower areas.

Anteralateral and posterior regions were evaluated in supine and sitting position, respectively. When patients were unable to maintain a sitting position, posterior regions were evaluated with the patients in left sitting position. The patients were asked to breathe in and out deeply before scanning.

The exam was conducted by dividing the chest wall in 12 regions, six for each lung: two anterior (upper and lower), two lateral and two posterior regions as described before [26]. In details, the anterior axillary line was used to divide anterior and lateral regions, the posterior axillary line divided lateral and posterior regions, while the inter nipple line split upper and lower areas.

Anteralateral and posterior regions were evaluated in supine and sitting position, respectively. When patients were unable to maintain a sitting position, posterior regions were evaluated with the patients in left sitting position. The patients were asked to breathe in and out deeply before scanning.
and right lateral decubitus.

We decided to exclude the left inferior anterior region because the presence of the heart might compromise the correct evaluation and the allocation of a reliable score, therefore leaving a total of 11 areas.

Each region was scored as follows:

- Score 0: regular pleural line, presence of horizontal artefacts (A-lines)
- Score 1: at least 3 B-lines in at least one scan of the region; the B-lines do not merge one in the other. Small subpleural consolidations $\leq$1 cm diameter may be present.
- Score 2: multiple, converging B-lines, usually determining a so-called “white lung”. Small subpleural consolidations $\leq$1 cm diameter may be present.
- Score 3: presence of at least one consolidation with major axis $>1$ cm.

The presence of pleural effusion was reported on the report form.

For each LUS we considered for analysis the total score, the total number of positive regions (NPR, number of regions with score $\geq$1), the anterolateral score and the presence or absence of consolidative lesions (score 3 in at least one region). The total score was calculated by summing the scores of all 11 lung regions (range: 0-21); the anterolateral score was derived by summing the anterior and lateral regional scores (range: 0-21).

2.2. Endpoints

In this study we analysed the association between the severity of pulmonary involvement by LUS at admission (as assessed by the total score, the NPR, the anterolateral scores, the presence of consolidations) and adverse outcomes in COVID-19 pneumonia. The primary outcome was death or ICU transfer. The secondary outcome was non-invasive mechanical ventilation support with continuous positive airway pressure (CPAP). In a subgroup of patients, we analysed the association between the burden of pulmonary involvement at LUS performed after 72 hours from the first examination (as assessed by total score) and the same outcomes.

2.3. Statistical analysis

Continuous variables were reported as medians and interquartile ranges. Categorical data were expressed as counts (percentages).

To assess the predictive value of the four ultrasound scores for the two outcomes, univariate and multivariate logistic regression analyses were conducted. We performed univariate analyses considering the ultrasound scores and the following parameters as potential confounders: age ($\leq$65, 66-75, $>75$ years), CCI (0; 1-2; 3-11), presence of hypertension, obesity (BMI $\leq$25; 25-30; $>30$) and P/F ($\leq$200, 200-300, $>300$). Only the variables statistically significant in univariate analysis were entered in multivariate models. Four separate multivariate analyses were performed using one of four LUS scores and the potential confounders statistically significant at the univariate stage.

Following the same statistical approach, we performed an additional analysis including only the patients who underwent LUS after 72 hours.

Results were expressed as odds ratio (OR) and 95% confidence interval (95% CI). P value $<0.05$, two tailed, was considered statistical significant.

In addition, for the total LUS scores at admission and after 72 hours, receiver operating characteristic (ROC) curve analyses were also performed to describe the ability of the score to predict the primary outcome. Sensitivity and specificity, with their 95% CIs, were calculated.

SAS software (release 9.4; SAS Institute, Inc., Cary, North Carolina) was used to perform statistical analysis.

### Table 2

| Lung ultrasound characteristics | Overall population (no. 190) |
|-------------------------------|-----------------------------|
| BILATERAL INVOLVEMENT - no. (%) | 173 (91.1) |
| CONSOLIDATIONS – no. (%)       | 46 (24.2) |
| No. Consolidations $\geq$2 – no. (%) | 31 (16.3) |
| Bilateral – no. (%)            | 31 (16.3) |
| PLEURAL EFFUSION - no. (%)     | 12 (6.3) |
| TOTAL SCORE – median (IQR)     | 10 (6-16) |
| NPR SCORE – median (IQR)       | 7 (5-10) |
| ANTEROLATERAL SCORE - median (IQR) | 5 (3-9) |
| REGIONAL INVOLVEMENT – no. (%) |                        |
| Consolidations – no. (%)       |                        |
| RIGHT UPPER ANTERIOR           | 89 (46.8) |
| RIGHT LOWER ANTERIOR           | 102 (53.7) |
| RIGHT UPPER LATERAL            | 106 (55.8) |
| RIGHT LOWER LATERAL            | 130 (68.4) |
| RIGHT UPPER POSTERIOR          | 121 (63.7) |
| RIGHT LOWER POSTERIOR          | 160 (84.2) |
| LEFT UPPER ANTERIOR            | 81 (42.6) |
| LEFT UPPER LATERAL             | 120 (63.2) |
| LEFT LOWER ANTERIOR            | 140 (73.7) |
| LEFT LOWER LATERAL             | 112 (58.9) |
| LEFT UPPER POSTERIOR           | 163 (85.8) |
| LEFT LOWER POSTERIOR           | 33 (17.4) |

NPR—Number of Positive Region; IQR—inter-quartile range.

3. Results

During the study period 243 patients were admitted to Internal Medicine COVID-19 wards with a diagnosis of COVID-19-related pneumonia; among them 6 met the exclusion criteria. Two hundred thirty-seven patients were eligible for the study; however 47 of them were excluded (30 patients did not undergo LUS at admission and 17 underwent LUS but incomplete reports made them not suitable for attribution of LUS scores).

The overall characteristics of the 190 patients included in the study are shown in Table 1.

The median age was 62 years (IQR 49-73) with a prevalence of male sex (59%).

Ten patients were transferred to ICU and 19 patients died; the primary composite outcome was observed in 25 patients (13.2%). Of the 165 remaining patients, 36 (21.8 %) were treated with CPAP.

The median time from the onset of symptoms to hospital admission was 8 days (IQR 5-12) and the median length of hospital stay was 12 days (IQR 7-20).

All enrolled patients underwent a chest X-ray in the Emergency Department: in 157 patients (84%) it showed the presence of interstitial and/or alveolar involvement, in 112 cases (59.9%) the involvement detected on X-ray was bilateral.

3.1. Lung ultrasound

LUS findings are presented in Table 2.

Pathological findings (B-lines pattern/consolidations, i.e. LUS score $\geq$ 1) were observed in 182 patients (95.8%) (Fig. 1). One hundred
seventy-three patients (91.1%) presented a bilateral lung involvement. No patient without bilateral involvement met the primary or secondary outcome.

Pleural effusion was observed in a minority of patients (6.3%). Consolidations were observed in 46 patients (24.2%). The analysis of regional score shows that the inferior-posterior regions were more frequently involved; these were as well the regions more frequently interested by consolidations (Fig. 2).

The median time of symptomatic disease before the first LUS was 9 days. In 73 out of 190 patients the examination at admission was performed within 7 days from symptoms’ onset. In this subset of population LUS showed a significantly lower total score (9 vs. 12; p 0.0128), NPR (6 vs. 8; p 0.0069) and anterolateral score (4 vs. 7; p 0.0067). The prevalence of consolidations at LUS was not significantly reduced in patients who had symptoms for less than 7 days (19.2% vs. 27.6%; p not significant).

One hundred twenty-eight patients were followed with LUS performed 3 days after the first examination. In this subset of patients, 10 reached the primary outcome; of the remaining 118 patients, 26 underwent CPAP. In 66 patients (51.5%) a worse total score was observed; 39 patients (30.5%) showed an improvement in total score, while in 23 patients (18%) LUS findings remained stable.

LUS scores stratified by the occurrence of the primary and secondary outcomes are shown in Table 3.

The results of univariate and multivariate analyses for both primary and secondary outcome are summarized in Table 4 and Supplementary Table 1.

The total LUS score, the anterolateral score and the NPR at admission were significantly associated with the risk of death or transfer to ICU (D-ICU). Among the confounders, age, P/F ratio and CCI were all associated to D-ICU at the univariate analysis, whereas BMI and hypertension were not.

Table 3

| LUS AT ADMISSION | PRIMARY OUTCOME | NON D/ICU (NO. 165) | D/ICU (NO. 25) |
|------------------|-----------------|--------------------|---------------|
| Total score - median (IQR) | 10 (6-16) | 10 (6-15) | 15 (12-20) |
| NPR score - median (IQR) | 7 (5-10) | 7 (4-10) | 10 (8-11) |
| Anterolateral score - median (IQR) | 5 (3-9) | 5 (2-8) | 9 (7-12) |
| Consolidation - no. (%) | 46 (24.2) | 38 (23.0) | 8 (32.0) |

| LUS AFTER 72 HOURS | PRIMARY OUTCOME | NON D/ICU (NO. 118) | D/ICU (NO. 22-24) |
|--------------------|-----------------|--------------------|-------------------|
| Total score - median (IQR) | 11 (6-16) | 11 (6-16) | 22 (22-24) |
| NPR score - median (IQR) | 7 (4-10) | 4 (2-7) | 8 (6-10) |
| Anterolateral score - median (IQR) | 5 (2-8) | 4 (2-7) | 8 (6-10) |
| Consolidation - no. (%) | 38 (23.0) | 22 (17.1) | 16 (44.4) |

Table 3 LUS scores and outcomes.

LUS=lung ultrasound; NPR=number of positive region; D/ICU=death or transfer to ICU; CPAP=continuous positive airways pressure; IQR=inter-quartile range.
Table 4
LUS at admission: univariate and multivariate analysis for primary and secondary outcome.

| PRIMARY OUTCOME (NUMBER OF PATIENTS=190) | UNIVARIATE ANALYSIS | MULTIVARIATE ANALYSES |
|------------------------------------------|----------------------|------------------------|
|                                          | OR (95% CI)          | p value                | OR (95% CI) | p value |
|------------------------------------------|----------------------|------------------------|-------------|---------|
| TOTAL SCORE                              | 1.16 (1.09-1.28)     | <0.0001                | -           | ns      |
| NPR SCORE                                | 1.36 (1.14-1.64)     | 0.0008                 | -           | ns      |
| ANTEROLATERAL SCORE                      | 1.25 (1.11-1.40)     | 0.0002                 | -           | ns      |
| CONSOLIDATION presence vs absence        | 1.57 (0.63-3.93)     | 0.3321                 | -           |         |
| AGE (years)                              | 0.0007               | ns                     |             |         |
| ≥66-75 vs ≤65                            | 1.72 (0.49-6.11)     | -                      | -           |         |
| >75 vs ≤65                               | 6.44 (2.42-17.10)    | -                      | -           |         |
| P/F (mmHg)                               | <0.0001              |                        |             |         |
| 200-300 vs >300                          | 4.60 (1.24-17.10)    | -                      | -           |         |
| ≤200 vs >300                             | 16.43 (5.39-50.04)   | -                      | -           |         |
| BMI (Kg/m²)                              | 0.0046               | ns                     |             |         |
| 1-2 vs 0                                 | 4.47 (0.86-23.12)    | -                      | -           |         |
| 3-11 vs 0                                | 10.74 (2.38-48.57)   | -                      | -           |         |
| P/F (mmHg)                               |                       |                        |             |         |
| ≥25 vs ≤25                               | 0.76 (0.24-2.42)     | -                      | -           |         |
| >30 vs ≤25                               | 1.29 (0.32-5.31)     | -                      | -           |         |
| HYPERTENSION presence vs absence         | 1.16 (0.48-2.78)     | 0.7461                 | -           |         |

SECONDARY OUTCOME (NUMBER OF PATIENTS=165)

| PRIMARY OUTCOME (NUMBER OF PATIENTS=190) | UNIVARIATE ANALYSIS | MULTIVARIATE ANALYSES |
|------------------------------------------|----------------------|------------------------|
|                                          | OR (95% CI)          | p value                | OR (95% CI) | p value |
|------------------------------------------|----------------------|------------------------|-------------|---------|
| TOTAL SCORE                              | 1.19 (1.10-1.28)     | <0.0001                | 1.14 (1.04-1.24) | 0.003   |
| NPR SCORE                                | 1.36 (1.17-1.58)     | <0.0001                | 1.26 (1.06-1.49) | 0.0091  |
| ANTEROLATERAL SCORE                      | 1.26 (1.13-1.40)     | <0.0001                | 1.20 (1.06-1.36) | 0.0037  |
| CONSOLIDATION presence vs absence        | 3.89 (1.74-8.67)     | 0.0009                 | -           | ns      |
| AGE (years)                              | 0.1112               |                        |             |         |
| ≥66-75 vs ≤65                            | 2.35 (0.95-5.83)     | -                      | -           |         |
| >75 vs ≤65                               | 2.08 (0.79-5.49)     | -                      | -           |         |
| P/F (mmHg)                               | <0.0001              |                        |             |         |
| 200-300 vs >300                          | 3.05 (1.07-8.69)     | -                      | -           |         |
| ≤200 vs >300                             | 25.11 (7.88-79.95)   | -                      | -           |         |
| BMI (Kg/m²)                              | 0.2816               |                        |             |         |
| 1-2 vs 0                                 | 0.45 (0.16-1.26)     | -                      | -           |         |
| 3-11 vs 0                                | 0.96 (0.41-2.20)     | -                      | -           |         |
| P/F (mmHg)                               |                       |                        |             |         |
| ≥25 vs ≤25                               | 0.59 (0.25-1.38)     | -                      | -           |         |
| >30 vs ≤25                               | 0.27 (0.06-1.27)     | -                      | -           |         |
| HYPERTENSION presence vs absence         | 1.04 (0.47-2.27)     | 0.9299                 | -           |         |

LUS=lung ultrasound; NPR=number of positive region; P/F=arterial oxygen partial pressure/fractional inspired oxygen ratio; CCI=Charlson Comorbidity Index; BMI=Body Mass Index; D/ICU=death or transfer to ICU; CPAP=continuous positive airways pressure; OR=Odds Ratio; CI=95% confidence interval; ns=not statistically significant.

a OR for 1-unit increase in LUS scores.

b LUS scores adjusted for age, P/F ratio and CCI.

c LUS scores adjusted for P/F ratio.

d P/F was the only factor associated to primary outcome in each multivariate analysis for different LUS scores. Therefore OR (95% CI) and p values for P/F in multivariate models are the same of univariate analysis.

P/F was the only confounder associated to secondary outcome in each multivariate analysis for different LUS scores. OR (95% CI) and p values for P/F in multivariate models are reported in Supplementary Table 1.

Table 5
LUS after 72 hours: univariate and multivariate analysis for primary and secondary outcome.

| PRIMARY OUTCOME (NUMBER OF PATIENTS=128) | UNIVARIATE ANALYSIS | MULTIVARIATE ANALYSIS |
|------------------------------------------|----------------------|------------------------|
|                                          | OR (95% CI)          | p value                | OR (95% CI) | p value |
|------------------------------------------|----------------------|------------------------|-------------|---------|
| TOTAL SCORE                              | 1.26 (1.14-1.40)     | <0.0001                | 1.24 (1.09-1.39) | 0.0001  |
| AGE (years)                              | 0.2091               |                        |             |         |
| 66-75 vs ≤65                             | 2.49 (0.84-7.39)     | -                      | -           |         |
| >75 vs ≤65                               | 1.83 (0.60-5.54)     | -                      | -           |         |
| P/F (mmHg)                               | 0.0003               | 0.0271                 |             |         |
| 200-300 vs >300                          | 1.98 (0.61-6.43)     | 0.70 (0.16-2.95)       | -           |         |
| ≤200 vs >300                             | 27.69 (5.43-141.20)  | 8.77 (1.54-49.85)      | -           |         |
| BMI (Kg/m²)                              | 0.3296               |                        |             |         |
| 1-2 vs 0                                 | 0.55 (0.17-1.74)     | -                      | -           |         |
| 3-11 vs 0                                | 1.36 (0.52-3.55)     | -                      | -           |         |
| P/F (mmHg)                               | 0.1176               |                        |             |         |
| 25-30 vs ≤25                             | 0.46 (0.17-1.22)     | -                      | -           |         |
| >30 vs ≤25                               | 0.26 (0.05-1.27)     | -                      | -           |         |
| HYPERTENSION presence vs absence         | 1.43 (0.59-3.45)     | 0.4231                 | -           |         |

LUS=lung ultrasound; P/F=arterial oxygen partial pressure/fractional inspired oxygen ratio; CCI=Charlson Comorbidity Index; BMI=Body Mass Index; D/ICU=death or transfer to ICU; CPAP=continuous positive airways pressure; OR=Odds Ratio; CI=95% confidence interval; ns=not statistically significant.

a OR for 1-unit increase in total score.

b Total score adjusted for P/F ratio. At multivariate analysis only total score resulted statistically significant.

c Total score adjusted for P/F ratio.

The three LUS variables associated to the primary outcome at the univariate analysis were evaluated in different multivariate analyses with age, P/F ratio and CCI. In all three cases, the only factor associated
with the primary outcome was P/F ratio.

Total score, anterolateral score, NPR and presence of consolidation were all associated to the secondary outcome at univariate analysis. Among the five confounders included in the analysis, only P/F ratio was associated to this outcome in the univariate analysis, whereas age, CCI, BMI and hypertension were not. At the multivariate analyses total score, anterolateral score and NPR maintained their significant association with the use of CPAP together with P/F ratio.

The results in the subgroup evaluated with a second LUS after 72 hours are reported in Table 5. In these patients the total score was associated to the primary outcome at univariate analysis together with P/F ratio. In the multivariate analysis, LUS score at 72 hours remained the only independent factor associated to D-ICU.

When considering the secondary outcome total score at 72 hours correlated to CPAP treatment; once again, the only confounder associated at the univariate analysis was P/F ratio. Total score at 72 hours and P/F ratio maintained the association to the use of CPAP at the multivariate analysis.

The ROC curve analysis results for the total LUS score at admission and after 72 hours are shown in Fig. 3. A total LUS score of 9 at admission is a reliable cut-off value to rule out death and ICU transfer (sensitivity 100%; specificity 45%). When considering LUS performed after 72 hours a cut-off value of 17 can accurately predict the primary outcome (sensitivity 89%; specificity 85%).

Among the 2090 scanned areas of admission LUS in the 190 patients, 110 were blindly reviewed. In 102 of the reviewed scans (92.7%) there was a perfect inter-observer reproducibility (same score allocated by the two independent observers).

4. Discussion

The main finding of our study in a population of consecutive patients with COVID-19 related pneumonia is that LUS performed after 72 hours is a reliable prognostic tool allowing to identify patients undergoing death or transfer to ICU. Furthermore even LUS at admission proved to be a valuable tool in predicting the development of respiratory failure death or transfer to ICU. Furthermore even LUS at admission proved to be a reliable prognostic tool allowing to identify patients undergoing death or transfer to ICU. Furthermore even LUS at admission proved to be a valuable tool in predicting the development of respiratory failure death or transfer to ICU. Furthermore even LUS at admission proved to be a valuable tool in predicting the development of respiratory failure death or transfer to ICU.

When considering the secondary outcome total score at 72 hours correlated to CPAP treatment; once again, the only confounder associated at the univariate analysis was P/F ratio. Total score at 72 hours and P/F ratio maintained the association to the use of CPAP at the multivariate analysis.

ROC curve analysis for the primary outcome (Area Under the Curve = 0.7625). b) LUS after 72 hours: ROC curve analysis for the primary outcome (Area Under the Curve = 0.8757).

Finally, none of the patients without bilateral involvement at LUS showed an adverse event (death, transfer to ICU and treatment with continuous positive airway pressure). Further studies are warranted to find out if LUS can be used as a rule out tool in settings such as Emergency Departments where it is crucial to identify patients who can be safely discharged.

These data together with the known practical advantages of being repeatable and quickly performed at bedside (thus limiting infectious patient transportation) confirm the potentiality of LUS in aiding the clinician in the risk stratification of the patient with COVID-19 pneumonia.
4.1. Limits

This study was monocentric so that the results may not be generalised for several reasons, starting from the prompt availability of portable machines (one every 15 beds) and the routinely use of LUS in both the wards before COVID-19 emergency.

Furthermore, physicians performing the examination were not blinded to patient clinical and radiological data.

Finally, 30 patients didn’t undergo LUS at admission probably as a consequence of the high workload of healthcare staff due to the huge number of daily admissions during the first days of COVID-19 emergency. Moreover in 17 patients incomplete LUS reports made examinations not suitable for attribution of LUS scores.

5. Conclusions

Our data suggest that LUS can be a promising prognostic tool in patients admitted to non-ICU units for COVID-19 pneumonia.

Further studies are warranted to confirm the same results and to assess the prognostic role of LUS in other settings such as Emergency Department or ICU units.

Funding

None.

Author contribution

F.C., E.C., and C.C conceived the idea and designed the project. F.L., M.B., G.C., and C.C. drafted the manuscript. G.C. conducted the statistical analyses. All the authors have revised the manuscript critically, approved the version submitted for publication and have agreed to be accountable for all aspects of the work.

Declaration of Competing Interest

The authors declare that they have no conflict of interests.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.ejim.2020.12.012.

References

[1] Istituto Superiore di Sanità. Characteristics of SARS-CoV-2 patients dying in Italy. Report based on available data on June 2020.
[2] Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X, Cui J, Xu W, Yang Y, Fayed ZA, Jacobil A, Li K, Li S, Shan H. CT imaging features of 2019 novel coronavirus (2019 nCoV). Radiology 2020;295:202–7. https://doi.org/10.1148/ radiol.2020200230.
[3] Shi H, Han X, Jiang N, Cao Y, Alward O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020;20(4):425–34. https://doi.org/10.1016/S1473-3099(20)30086-4.
[4] Lichtenstein DA, Meziere GA. Relevance of lung ultrasound in the diagnosis of acute respiratory failure. The BLUE protocol. Chest 2008;134(1):117–25. https://doi.org/10.1378/chest.07-2680.
[5] Mojoli F, Bouhemad B, Mongodi S, et al. Lung ultrasound for critically ill patients. Am J Respir Crit Care Med 2019;199(6):701–14. https://doi.org/10.1164/rccm.201802-02636C.
[6] Mayo PH, Copetti R, Feller-Kopman D, Mathis G, Maury E, Mongodi S, et al. Thoracic ultrasonography: a narrative review. Intensive Care Med 2019;45(9):1200–11. https://doi.org/10.1007/s00134-019-05725-8.
[7] Ticinesi A, Laurentini F, Pouvenne A, Mori G, Chiussi G, Maggio M, Meschi T. Lung ultrasound and chest x-ray for detecting pneumonia in an acute geriatric ward. Medicine 2016;95(27):e4153. https://doi.org/10.1097/MD.0000000000004153.